The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease in a Randomized Trial
Open accessAbstract
BACKGROUND & AIMS There is limited evidence that a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) reduces gut symptoms in quiescent inflammatory bowel disease (IBD). We performed a randomized, controlled trial to investigate the effects of a low-FODMAP diet on persistent gut symptoms, the intestinal microbiome, and circulating markers of inflammation in patients with quiescent IBD. METHODS We performed a single-blind trial of 52 patients with quiescent Crohn's disease or ulcerative colitis and persistent gut symptoms at 2 large gastroenterology clinics in the United Kingdom. Patients were randomly assigned to groups that followed a diet low in FODMAPs (n=27) or a control diet (n=25), with dietary advice, for 4 weeks. Gut symptoms and health-related quality of life were measured using validated questionnaires. Stool and blood samples were collected at baseline and end of trial. We assessed fecal microbiome composition and function using shotgun metagenomic sequencing and phenotypes of T cells in blood using flow cytometry. RESULTS A higher proportion of patients reported adequate relief of gut symptoms following the low-FODMAP diet (14/27, 52%) than the control diet (4/25, 16%, P=.007). Patients had a greater reduction in irritable bowel syndrome severity scores following the low-FODMAP diet (mean reduction of 67; standard error, 78) than the control diet (mean reduction of 34; standard error, 50), although this difference was not statistically significant (P=.075). Following the low-FODMAP diet, patients had higher health-related quality of life scores (81.9±1.2) than patients on the control diet (78.3±1.2, P=.042). A targeted analysis revealed that in stool samples collected at the end of the study period, patients on the low-FODMAP diet had significantly lower abundance of Bifidobacterium adolescentis, B longum, and Faecalibacterium prausnitzii than patients on control diet. However, microbiome diversity and markers of inflammation did not differ significantly between groups. CONCLUSIONS In a trial of the low-FODMAP diet vs a control diet in patients with quiescent IBD, we found no significant difference after 4 weeks in change in irritable bowel syndrome severity scores, but significant improvements in specific symptom scores and numbers reporting adequate symptom relief. The low-FODMAP diet reduced fecal abundance of microbes believed to regulate the immune response, compared with the control diet, but had no significant effect on markers of inflammation. We conclude that a 4-week diet low in FODMAPs is safe and effective for managing persistent gut symptoms in patients with quiescent IBD. www.isrctn.com no: ISRCTN17061468.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413
Stool form scale as a useful guide to intestinal transit time
Lewis, S. J., & Heaton, K. W. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709011203 · Cited by 3,244
A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY
Harvey, R. F., & Bradshaw, J. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)92767-1 · Cited by 2,959
An integrated catalog of reference genes in the human gut microbiome
MetaHIT Consortium, Li, J., Jia, H., Cai, X., Zhong, H., Feng, Q., Sunagawa, S., Arumugam, M., Kultima, J. R., Prifti, E., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2942 · Cited by 2,164
Self-citationDietary intervention impact on gut microbial gene richness
Cotillard, A., Kennedy, S. P., Kong, L. C., Prifti, E., Pons, N., Le Chatelier, E., Almeida, M., Quinquis, B., Levenez, F., Galleron, N., et al. (2013) · Nature · doi:10.1038/nature12480 · Cited by 1,832
Self-citationFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Svedlund, J., Sj�din, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,468
A Diet Low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome
Halmos, E. P., Power, V. A., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.09.046 · Cited by 1,249
Dynamics of the human gut microbiome in inflammatory bowel disease
Halfvarson, J., Brislawn, C. J., Lamendella, R., Vázquez-Baeza, Y., Walters, W. A., Bramer, L. M., D'Amato, M., Bonfiglio, F., McDonald, D., Gonzalez, A., et al. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.4 · Cited by 1,204
MetaHIT Consortium, Nielsen, H. B., Almeida, M., Juncker, A. S., Rasmussen, S., Li, J., Sunagawa, S., Plichta, D. R., Gautier, L., Pedersen, A. G., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2939 · Cited by 1,184
Self-citationLewis, J. D., Chuai, S., Nessel, L., Lichtenstein, G. R., Aberra, F. N., & Ellenberg, J. H. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20520 · Cited by 964
Towards standards for human fecal sample processing in metagenomic studies
Costea, P. I., Zeller, G., Sunagawa, S., Pelletier, E., Alberti, A., Levenez, F., Tramontano, M., Driessen, M., Hercog, R., Jung, F.-E., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3960 · Cited by 893
Self-citationQuévrain, E., Maubert, M. A., Michon, C., Chain, F., Marquant, R., Tailhades, J., Miquel, S., Carlier, L., Bermúdez-Humarán, L. G., Pigneur, B., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-307649 · Cited by 841
A microbial signature for Crohn's disease
Pascal, V., Pozuelo, M., Borruel, N., Casellas, F., Campos, D., Santiago, A., Martinez, X., Varela, E., Sarrabayrouse, G., Machiels, K., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313235 · Cited by 822
Diets that differ in their FODMAP content alter the colonic luminal microenvironment
Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Gibson, P. R., & Muir, J. G. (2015) · Gut · doi:10.1136/gutjnl-2014-307264 · Cited by 681
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607
Staudacher, H. M., Lomer, M. C. E., Anderson, J. L., Barrett, J. S., Muir, J. G., Irving, P. M., & Whelan, K. (2012) · The Journal of Nutrition · doi:10.3945/jn.112.159285 · Cited by 590
Self-citationCosta, F., Mumolo, M. G., Ceccarelli, L., Bellini, M., Romano, M. R., Sterpi, C., Ricchiuti, A., Marchi, S., & Bottai, M. (2005) · Gut · doi:10.1136/gut.2004.043406 · Cited by 550
Shepherd, S. J., Parker, F. C., Muir, J. G., & Gibson, P. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.02.058 · Cited by 549
Blake, M. R., Raker, J. M., & Whelan, K. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13746 · Cited by 495
Self-citationSpecies–function relationships shape ecological properties of the human gut microbiome
Vieira-Silva, S., Falony, G., Darzi, Y., Lima-Mendez, G., Garcia Yunta, R., Okuda, S., Vandeputte, D., Valles-Colomer, M., Hildebrand, F., Chaffron, S., et al. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.88 · Cited by 483
FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial
McIntosh, K., Reed, D. E., Schneider, T., Dang, F., Keshteli, A. H., De Palma, G., Madsen, K., Bercik, P., & Vanner, S. (2017) · Gut · doi:10.1136/gutjnl-2015-311339 · Cited by 478
Staudacher, H. M., Lomer, M. C. E., Farquharson, F. M., Louis, P., Fava, F., Franciosi, E., Scholz, M., Tuohy, K. M., Lindsay, J. O., Irving, P. M., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.010 · Cited by 430
Self-citationBARRETT, J. S., GEARRY, R. B., MUIR, J. G., IRVING, P. M., ROSE, R., ROSELLA, O., HAINES, M. L., SHEPHERD, S. J., & GIBSON, P. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04237.x · Cited by 403
Self-citationSystematic review with meta-analysis: The efficacy of probiotics in inflammatory bowel disease
Derwa, Y., Gracie, D. J., Hamlin, P. J., & Ford, A. C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14203 · Cited by 393
The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS
Staudacher, H. M., & Whelan, K. (2017) · Gut · doi:10.1136/gutjnl-2017-313750 · Cited by 387
Self-citationGearry, R. B., Irving, P. M., Barrett, J. S., Nathan, D. M., Shepherd, S. J., & Gibson, P. R. (2009) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2008.09.004 · Cited by 322
Self-citationMajor, G., Pritchard, S., Murray, K., Alappadan, J. P., Hoad, C. L., Marciani, L., Gowland, P., & Spiller, R. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.062 · Cited by 302
Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity
Lin, J.-F., Chen, J.-M., Zuo, J.-H., Yu, A., Xiao, Z.-J., Deng, F.-H., Nie, B., & Jiang, B. (2014) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000057 · Cited by 296
Cholapranee, A., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14030 · Cited by 296
Whelan, K., Martin, L. D., Staudacher, H. M., & Lomer, M. C. E. (2018) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.12530 · Cited by 290
Self-citationVarela, E., Manichanh, C., Gallart, M., Torrejón, A., Borruel, N., Casellas, F., Guarner, F., & Antolin, M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12365 · Cited by 249
Halmos, E. P., Christophersen, C. T., Bird, A. R., Shepherd, S. J., Muir, J. G., & Gibson, P. R. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.22 · Cited by 210
Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease
Pedersen, N., Ankersen, D. V., Felding, M., Wachmann, H., Végh, Z., Molzen, L., Burisch, J., Andersen, J. R., & Munkholm, P. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i18.3356 · Cited by 209
Comparative effects of six probiotic strains on immune function in vitro
Dong, H., Rowland, I., & Yaqoob, P. (2012) · British Journal of Nutrition · doi:10.1017/s0007114511005824 · Cited by 197
Bodger, K., Ormerod, C., Shackcloth, D., Harrison, M., & Collaborative, O. B. O. T. I. C. (2014) · Gut · doi:10.1136/gutjnl-2013-305600 · Cited by 194
Prince, A. C., Myers, C. E., Joyce, T., Irving, P., Lomer, M., & Whelan, K. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000708 · Cited by 190
Self-citationThe challenges of control groups, placebos and blinding in clinical trials of dietary interventions
Staudacher, H. M., Irving, P. M., Lomer, M. C. E., & Whelan, K. (2017) · Proceedings of The Nutrition Society · doi:10.1017/s0029665117000350 · Cited by 185
Self-citationPlacebo effects and their determinants in gastrointestinal disorders
Elsenbruch, S., & Enck, P. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.117 · Cited by 173
Fischer, A., Zundler, S., Atreya, R., Rath, T., Voskens, C., Hirschmann, S., López-Posadas, R., Watson, A., Becker, C., Schuler, G., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310022 · Cited by 169
Moens, F., Weckx, S., & Vuyst, L. D. (2016) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2016.05.015 · Cited by 161
Cox, S. R., Prince, A. C., Myers, C. E., Irving, P. M., Lindsay, J. O., Lomer, M. C. E., & Whelan, K. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx073 · Cited by 154
Self-citationNg, S. C., Benjamin, J. L., McCarthy, N. E., Hedin, C. R. H., Koutsoumpas, A. L., Plamondon, S., Price, C. L., Hart, A. L., Kamm, M. A., Forbes, A., et al. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21590 · Cited by 151
Self-citationThe UK IBDQ—A British version of the inflammatory bowel disease questionnaire
Cheung, W., Garratt, A., Russell, I. T., & Williams, J. G. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00152-3 · Cited by 149
Hedin, C. R. H., McCarthy, N. E., Louis, P., Farquharson, F. M., McCartney, S. A., Taylor, K. M., Prescott, N. J., Murrells, T., Stagg, A. J., Whelan, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-306226 · Cited by 148
Self-citationAdequate Relief as an Endpoint in Clinical Trials in Irritable Bowel Syndrome
Mangel, A. W., Hahn, Heath, A., Northcutt, A., Kong, S., Dukes, G., & McSorley, D. (1998) · Journal of International Medical Research · doi:10.1177/030006059802600203 · Cited by 144
Staudacher, H. M., Ralph, F. S. E., Irving, P. M., Whelan, K., & Lomer, M. C. E. (2019) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2019.01.017 · Cited by 134
Self-citationShen, Z., Zhu, C., Quan, Y., Yang, J., Yuan, W., Yang, Z., Wu, S., Luo, W., Tan, B., & Wang, X. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14144 · Cited by 133
Gracie, D. J., Williams, C. J. M., Sood, R., Mumtaz, S., Bholah, M. H., Hamlin, P. J., & Ford, A. C. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.05.012 · Cited by 116
Quigley, E. M. M. (2015) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x15621230 · Cited by 93
Eswaran, S. L., Dolan, R. D., Ball, S. C., Jackson, K., & Chey, W. D. (2019) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2019.03.003 · Cited by 77
van Hoboken, E. A., Thijssen, A. Y., Verhaaren, R., van der Veek, P. P. J., Prins, F. A., Verspaget, H. W., & Masclee, A. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.579156 · Cited by 74
Azathioprine therapy selectively ablates human Vδ2+ T cells in Crohn’s disease
McCarthy, N. E., Hedin, C. R. H., Sanders, T. J., Amon, P., Hoti, I., Ayada, I., Baji, V., Giles, E. M., Wildemann, M., Bashir, Z., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80840 · Cited by 50
Self-citation
Cited by
Mayer, E. A., Nance, K., & Chen, S. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042320-014032 · Cited by 813
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
The interplay between diet and the gut microbiome: implications for health and disease
Ross, F. C., Patangia, D., Grimaud, G., Lavelle, A., Dempsey, E. M., Ross, R. P., & Stanton, C. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01068-4 · Cited by 638
Faecalibacterium: a bacterial genus with promising human health applications
Martín, R., Rios-Covian, D., Huillet, E., Auger, S., Khazaal, S., Bermúdez-Humarán, L. G., Sokol, H., Chatel, J.-M., & Langella, P. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad039 · Cited by 566
Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health
Zhang, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179588 · Cited by 416
Metadata
- Authors
- Cox, S. R., Lindsay, J. O., Fromentin, S., Stagg, A. J., McCarthy, N. E., Galleron, N., Ibraim, S. B., Roume, H., Levenez, F., Pons, N., Maziers, N., Lomer, M. C., Ehrlich, S. D., Irving, P. M., & Whelan, K.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 158
- Issue
- 1
- Pages
- 176-188.e7
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2978624250
- Cited by
- 382
- References
- 54
- FWCI
- 21.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.